HT-6184

Phase 2Small molecule

HHalia Therapeutics, Inc.

HT-6184 is one of 53 small molecule programs targeting Myelodysplastic Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromeActive, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

61 competitors in Myelodysplastic Syndrome

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Approved

42 2

Neoral

Novartis

Approved

10 3

Exjade

Novartis

Approved

5 4

Cytosar

Teva

Phase 3

41 5

Venclexta

AbbVie

Phase 3

17 6

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

60 7

Fludara

Sanofi

Phase 3

16 8

Danocrine

Rocaltrol

Afinitor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Myelodysplastic Syndrome

NCT07052006

Clinical

Trials by Indication[1]

Semaglutide1 trial

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

Withdrawn·HHalia Therapeutics, Inc.·Phase 2·NCT07172867

Inflammation1 trial

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

Completed·HHalia Therapeutics, Inc.·Phase 2·NCT06241742·81 enrolled

Myelodysplastic Syndrome1 trial

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia

Active, not recruiting·HHalia Therapeutics, Inc.·Phase 2·NCT07052006·37 enrolled

Unspecified1 trial

Study to Evaluate HT-6184 in Healthy Subjects

Completed·HHalia Therapeutics, Inc.·Phase 1·NCT05447546·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for HT-6184. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HT-6184 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HT-6184. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Halia Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHalia Therapeutics, Inc.

HT-6184

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Semaglutide1 trial

Inflammation1 trial

Myelodysplastic Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News